Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
Completed · Phase 1
Conditions studied: Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
In brief
RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with gemcitabine may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining erlotinib with gemcitabine in treating patients who have newly diagnosed locally advanced or metastatic pancreatic cancer or other solid tumors.
Key facts
- Study ID
- NCT00033241
- Run by
- OSI Pharmaceuticals
- Starts
- 2001-07-23
- Expected to finish
- 2004-04-22
- Last updated by the study team
- 2018-01-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arizona Cancer Center at University of Arizona Health Sciences Center — Tucson, Arizona, United States
- Cancer Therapy and Research Center — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.